| For: | Chen YJ, Tang QB, Zou SQ. Inactivation of RASSF1A, the tumor suppressor gene at 3p21.3 in extrahepatic cholangiocarcinoma. World J Gastroenterol 2005; 11(9): 1333-1338 [PMID: 15761971 DOI: 10.3748/wjg.v11.i9.1333] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i9/1333.htm |
| Number | Citing Articles |
| 1 |
Antje M. Richter, Miriam M. Küster, Michelle L. Woods, Sara K. Walesch, Mira Y. Gökyildirim, Marcus Krueger, Reinhard H. Dammann. RASSF10 Is a TGFβ-Target That Regulates ASPP2 and E-Cadherin Expression and Acts as Tumor Suppressor That Is Epigenetically Downregulated in Advanced Cancer. Cancers 2019; 11(12) doi: 10.3390/cancers11121976
|
| 2 |
Antje M. Richter, Michelle L. Woods, Miriam M. Küster, Sara K. Walesch, Thomas Braun, Thomas Boettger, Reinhard H. Dammann. RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice. Oncogene 2020; 39(15) doi: 10.1038/s41388-020-1195-6
|
| 3 |
Hong Li, Shaoqin Chen, Yi Shu, Yongjun Chen, Ying Su, Xin Wang, Shengquan Zou. Synergy of DNA methylation and histone deacetylase inhibitors in the re-expression of RASSF1A and P16 genes silenced in QBC cells. The Chinese-German Journal of Clinical Oncology 2008; 7(11) doi: 10.1007/s10330-008-0119-7
|
| 4 |
Iris Tischoff, Christian Wittekind, Andrea Tannapfel. Role of epigenetic alterations in cholangiocarcinoma. Journal of Hepato-Biliary-Pancreatic Surgery 2006; 13(4) doi: 10.1007/s00534-005-1055-3
|
| 5 |
Lang Hu, Gang Chen, Hongping Yu, Xiaoqiang Qiu. Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatology International 2010; 4(1) doi: 10.1007/s12072-010-9164-8
|
| 6 |
So-Hyun Shin, Kyoungbun Lee, Baek-Hui Kim, Nam-Yun Cho, Jin-Young Jang, Yong-Tae Kim, Donguk Kim, Ja June Jang, Gyeong Hoon Kang. Bile-Based Detection of Extrahepatic Cholangiocarcinoma with Quantitative DNA Methylation Markers and Its High Sensitivity. The Journal of Molecular Diagnostics 2012; 14(3) doi: 10.1016/j.jmoldx.2012.01.014
|
| 7 |
Hege Marie Vedeld, Trine Folseraas, Guro Elisabeth Lind. Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis – The promise of DNA methylation and molecular biomarkers. JHEP Reports 2020; 2(5) doi: 10.1016/j.jhepr.2020.100143
|
| 8 |
Patricia García, Carlos Manterola, Juan Carlos Araya, Miguel Villaseca, Pablo Guzmán, Antonio Sanhueza, Melanie Thomas, Héctor Alvarez, Juan Carlos Roa. Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions. Molecular Carcinogenesis 2009; 48(1) doi: 10.1002/mc.20457
|
| 9 |
Pablo Letelier, Priscilla Brebi, Oscar Tapia, Juan Carlos Roa. DNA promoter methylation as a diagnostic and therapeutic biomarker in gallbladder cancer. Clinical Epigenetics 2012; 4(1) doi: 10.1186/1868-7083-4-11
|
| 10 |
Boris R.A. Blechacz, Gregory J. Gores. Molecular Genetics of Liver Neoplasia. 2010; doi: 10.1007/978-1-4419-6082-5_5
|
| 11 |
Naohiko Kohya, Yasuo Koga, Yoshihiko Kitajima, Kohji Miyazaki. Aberrant promoter hypermethylation in biliary tract carcinoma. Journal of Hepato-Biliary-Pancreatic Surgery 2006; 13(4) doi: 10.1007/s00534-005-1058-0
|
| 12 |
Tania Pérez Cala. Factores genéticos y epigenéticos del cáncer gástrico. Actualidades Biológicas 2017; 39(106) doi: 10.17533/udea.acbi.v39n106a01
|
| 13 |
Yongjun Chen, Jian Luo, Rui Tian, Huawen Sun, Shengquan Zou. miR-373 Negatively Regulates Methyl-CpG-Binding Domain Protein 2 (MBD2) in Hilar Cholangiocarcinoma. Digestive Diseases and Sciences 2011; 56(6) doi: 10.1007/s10620-010-1481-1
|
| 14 |
Shi Zuo, Yongjun Chen, Lining Xu, Qibin Tang, Shengquan Zou. Re-expression of RASSF1A by 5-Aza-CdR induced demethylation of the promoter region in human biliary tract carcinoma cells. Journal of Huazhong University of Science and Technology 2007; 27(3) doi: 10.1007/s11596-007-0316-6
|
| 15 |
Jennifer Yang, Matthew R. Farren, Daniel Ahn, Tanios Bekaii-Saab, Gregory B. Lesinski. Signaling pathways as therapeutic targets in biliary tract cancer. Expert Opinion on Therapeutic Targets 2017; 21(5) doi: 10.1080/14728222.2017.1306055
|
| 16 |
Huey-Ling You, Wan-Ting Huang, Ting-Ting Liu, Shao-Wen Weng, Hock-Liew Eng. Mutations of candidate tumor suppressor genes at chromosome 3p in intrahepatic cholangiocarcinoma. Experimental and Molecular Pathology 2017; 103(3) doi: 10.1016/j.yexmp.2017.11.002
|
| 17 |
Dhanpat Jain, William Ahrens, Sydney Finkelstein. Molecular Evidence for the Neoplastic Potential of Hepatic Von-Meyenburg Complexes. Applied Immunohistochemistry & Molecular Morphology 2010; 18(2) doi: 10.1097/PAI.0b013e3181b94fd8
|
| 18 |
Chiara Braconi, Nianyuan Huang, Tushar Patel. Microrna-Dependent Regulation of Dna Methyltransferase-1 and Tumor Suppressor Gene Expression by Interleukin-6 in Human Malignant Cholangiocytes. Hepatology 2010; 51(3) doi: 10.1002/hep.23381
|
| 19 |
Vishwas Parekh, Deniz Peker. Malignant Transformation in Von-Meyenburg Complexes. Applied Immunohistochemistry & Molecular Morphology 2015; 23(9) doi: 10.1097/PAI.0000000000000132
|
| 20 |
Ali Reza Safarpour, Hassan Askari, Farshid Ejtehadi, Asaad Azarnezhad, Ehsan Raeis-Abdollahi, Amir Tajbakhsh, Mohammad Foad Abazari, Firoozeh Tarkesh, Alireza Shamsaeefar, Ramin Niknam, Gholam Reza Sivandzadeh, Kamran Bagheri Lankarani, Fardad Ejtehadi. Cholangiocarcinoma and liver transplantation: What we know so far?. World Journal of Gastrointestinal Pathophysiology 2021; 12(5): 84-105 doi: 10.4291/wjgp.v12.i5.84
|
| 21 |
Matthew A. Cooley, Amber R. Schneider, Emily G. Barr Fritcher, Dragana Milosevic, Michael J. Levy, Amber R. Bridgeman, John A. Martin, Bret T. Petersen, Barham K. Abu Dayyeh, Andrew C. Storm, Ryan J. Law, Eric J. Vargas, Vishal Garimella, Tyler Zemla, Sarah M. Jenkins, Jun Yin, Gregory J. Gores, Lewis R. Roberts, Benjamin R. Kipp, Vinay Chandrasekhara. Utility of methylated DNA markers for the diagnosis of malignant biliary strictures. Hepatology 2025; 81(2) doi: 10.1097/HEP.0000000000000970
|